Trending News

#Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK COVID-19 vaccine delayed

Sanofi and GSK have announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase I/II study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna doses first participants in Phase II/III COVID-19 vaccine in adolescents

Moderna has announced that the first adolescent participants have been dosed in the Phase II/ III study of mRNA-1273, its vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine: latest efficacy results released

University of Oxford and AstraZeneca researchers have released a pooled analysis of Phase III trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of Phase III data from studies of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine: helps antibodies last for three months

In a letter published in the New England Journal of Medicine, Moderna has reported that participants in the Phase I study its mRNA-1273 COVID-19 vaccine candidate, retained high levels of neutralising antibodies for 119 days following first vaccination (90 days following second vaccination). The study was led by the National Institute… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Pfizer vaccine approval: biotech innovation brings positivity for UK private sector

This week has provided hope and optimism that the end of the pandemic is finally in sight, with the UK becoming the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine for widespread use. With almost half of Britain now in Tier 3 and many small businesses facing… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Marketing approval authorisation

Pfizer / BioNTech vaccine approved and available for use in the UK next week

The Pfizer/BioNTech COVID-19 vaccine has been authorised for emergency use by the Medicines and Healthcare Products Regulatory Authority (MHRA). Pfizer and BioNTech recently announced final efficacy analysis in their Phase III study for their mRNA-based COVID-19 vaccine candidate BNT162b2, which showed an efficacy rate of 95% in participants without prior… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna to supply UK government with an extra 2 million vaccine doses

Moderna will supply the UK government with an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. “We appreciate the collaboration with the UK government as with many other governments and other key… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine 70% effective

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. Following the trial reaching the target for interim analysis, the independent Data… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford coronavirus vaccine produces strong immune response in older adults

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Vaccines

Pfizer and BioNTech conclude Phase III study of Covid-19 vaccine, showing 95% efficacy

Pfizer and BioNTech have announced that after conducting the final efficacy analysis in their ongoing Phase III study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna announces supply agreement with UK government for COVID-19 vaccine

Moderna has announced a supply agreement with the UK government to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities. This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Interim clinical trial results of NIH-Moderna COVID-19 vaccine show 94% efficacy

The investigational NIH-Moderna COVID-19 vaccine mRNA-1273 has been found to be safe and effective at preventing symptomatic COVID-19 in adults. This is according to the interim results reviewed by an independent data and safety monitoring board (DSMB) overseeing the Phase III trial of the investigational COVID-19 vaccine mRNA-1273. The interim… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Johnson & Johnson starts second global phase III trial of Janssen COVID-19 vaccine candidate

The Janssen COVID-19 vaccine candidate leverages the company’s AdVac technology platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac technology platform has been used to vaccinate more than 110,000 people to date across… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Russia says Sputnik V vaccine against COVID-19 phase III clinical trials shows 92% efficacy

The National Research Center for Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced that the Sputnik V vaccine demonstrated high efficacy of 92%. The human adenoviral vectors vaccine against coronavirus was registered on the 11 August under the emergency use authorisation mechanism. The confirmation… Read More

#Covid-19 #Editor's Choice #News #Trending News